News | PET-CT | June 09, 2017

Offers Patient Comfort and Safety

Toshiba Medical launches its new Celesteion PUREViSION Edition PET/CT system to help diagnose and treat oncology patients

Toshiba Medical launches its new Celesteion PUREViSION Edition PET/CT system to help diagnose and treat oncology patients.


Oncologists have access to advanced imaging technologies for excellent cancer patient care with the new Celesteion PUREViSION Edition PET/CT system from Toshiba Medical, a Canon Group company. The newest edition of Celesteion allows for ease and efficiency in PET/CT, CT simulation and diagnostic CT exams, to help diagnose and treat oncology patients. The system’s patient-centered design can help deliver a safe and comfortable experience, facilitating better patient compliance.

The Celesteion PUREViSION Edition presents a significant advancement in PET/CT resolution and reconstruction. Offering 70 cm true field-of-view, as well as Toshiba Medical’s SUREFLiGHT reconstruction technology, including Point Spread Function and Time of Flight techniques, the system offers oncologists sharp images and high contrast for improved visualization of small tumors throughout the body. The system’s PUREViSION 16-row CT detector assists in acquiring high-quality CT images, while SEMARTM helps reduce artifacts caused by metal implants, allowing providers to view more clinical information.

Prioritizing patient comfort, the Celesteion PUREViSION Edition features an industry-leading 90 cm wide CT bore that creates a sense of openness to put patients at ease and offers versatile positioning for optimal treatment planning. Ensuring clinicians don’t have to choose between efficiency and safety, the system also comes standard with AIDR 3D iterative dose reduction technology.

“We developed the Celesteion PUREViSION Edition with our customers’ needs in mind,” said Dominic Smith, senior director, CT, PET/CT, and MR Business Units, Toshiba America Medical Systems, Inc. “Accuracy is everything when treating oncology patients and Toshiba Medical is committed to providing our customers with the high-quality imaging solutions they require to provide efficient, effective patient care.”

Toshiba Medical will showcase the Celesteion PUREViSION Edition at this year’s Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual meeting in Denver, June 10–14, 2017.

For more information: www.medical.toshiba.com


Related Content

News | PET Imaging

Jun. 24, 2025 — GE HealthCare has announced that the U.S. Food and Drug Administration (FDA) approved an updated label ...

Time June 24, 2025
arrow
News | PET Imaging

June 19, 2025 – dGenThera, Inc., a biotechnology company pioneering theranostic molecular pairs, and Nusano, a physics ...

Time June 24, 2025
arrow
News | PET-CT

June 23, 2025 — GE HealthCare’s commitment to advancing precision care in cardiology through its molecular imaging ...

Time June 23, 2025
arrow
News | Nuclear Imaging

June 23, 2025 — Serac Imaging Systems Ltd. and its clinical investigators from The Ohio State University Wexner Medical ...

Time June 23, 2025
arrow
News | Breast Imaging

May 13, 2025 — In one of the larger studies of its kind, researchers have identified six breast texture patterns that ...

Time May 16, 2025
arrow
News | Computed Tomography (CT)

Feb. 25, 2025 —Stratasys Ltd. and Siemens Healthineers recently presented the results of a joint research effort that ...

Time March 04, 2025
arrow
News | Artificial Intelligence

Feb. 4, 2025 — Riverain Technologies recently announced it expanded across eight countries in 2024 and added nearly 50 ...

Time February 04, 2025
arrow
News | Artificial Intelligence

Dec. 12, 2024 — At RSNA 2024, Careverse officially made its debut, exhibiting in the AI Showcase area, sharing its ...

Time December 18, 2024
arrow
News | Artificial Intelligence

Dec. 17, 2024 — Radin Health, a provider of advanced radiology AI-Powered solutions, highlighted its All-in-One ...

Time December 18, 2024
arrow
News | Computed Tomography (CT)

Dec. 3, 2024 — During RSNA '24, GE HealthCare announced the 510(k) submission to the U.S. Food and Drug Administration ...

Time December 18, 2024
arrow
Subscribe Now